Q3 2025 Urogen Pharma Ltd Earnings Call Transcript

Nov 6, 2025 / 03:00 PM GMT

Release Date Price: $21.64 (+12.55%)

Transcript 10-Q8-K

Key Points

Positve

UroGen Pharma Ltd (URGN) reported a significant increase in preliminary demand revenue for October, more than doubling the previous three months.
The company has secured broad coverage across major payers, with more than 95% of covered lives having access to their products.
UroGen Pharma Ltd (URGN) has expanded its sales force to 82 representatives, enhancing its commercial infrastructure.
The company is on track to submit an NDA for EGN 103 in the second half of 2026, with potential approval anticipated in 2027.
UroGen Pharma Ltd (URGN) has a solid balance sheet with cash equivalents and marketable securities totaling $127.4 million as of September 30, 2025.

Negative

The uptake of Zyturi has been slower than expected due to logistical and operational challenges, including reimbursement concerns.
There is a 45 to 60 day lag between patient enrollment form submission and patient dosing, primarily due to administrative hurdles.
The company is currently navigating the temporary use of a miscellaneous J Code, which adds complexity to reimbursement processes.
R&D expenses increased by $2.6 million compared to the same period in 2024, driven by costs associated with the Phase 3 Utopia trial.
Net loss for the third quarter of 2025 was $33.3 million, an increase from the $23.7 million net loss in the same period in 2024.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

URGN.OQ - Urogen Pharma Ltd
Q3 2025 Urogen Pharma Ltd Earnings Call
Nov 06, 2025 / 03:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and thank you for standing by. Welcome to the Eurogen Farmer 3rd quarter 2025 earnings call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised today's conference is being recorded. I'd now like to go ahead and hand the conference over to your first speaker today, Vincent Peron, Investor relations. Vincent, you have the floor.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.